Publication | Open Access

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

UrologySurgical OncologyGenitourinary CancerMedicineSurgeryCheckmate 914OncologyNephrologyKidney ResearchIpilimumab Versus Placebo